Marketing Director
ROLE OVERVIEW
Connecting and meeting with business partners, fellow innovators and key advisers is a vital part of everyone's endeavours since it enables knowledge exchange and onward contact for mutual and collective success.
Raise Your Profile
Whether you are looking to attract a new business client, investment and partnering deal flow or talent, among other goals, One Nucleus offers a wide range of opportunities to raise your profile to our members and to the Greater Cambridge cluster in particular.
Discounts for Members
Members can take advantage of discounts on a wide range of products and services to maximise their return on the member subscription, often recovering multiples of the fees paid. Receive discounted rates on laboratory supplies, services, key industry events and more.
Connect with Our Network
A key advantage to any company joining One Nucleus is the ability to connect to potential partners, investors, service providers, clients and their peers for knowledge-sharing. We do this through our varied range of informative networking events, which tend to be situated throughout Cambridge and London.
Build the Best Teams
One Nucleus recognises that a company’s employees are its most valuable asset and the competition for talented and skilled employees has never been fiercer in the region’s life science sector. One Nucleus offers a range of services and engagement opportunities in this critical area to help support our members and maintain the reputation of the sector.
Events
Connecting and meeting with business partners, fellow innovators and key advisers is a vital part of everyone's endeavours since it enables knowledge exchange and onward contact for mutual and collective success. Complementing the wider One Nucleus support activities our portfolio of events is designed to meet the needs of our network in terms of content, format, timing, peer-to-peer engagements and modes of delivery.
Membership Overview
With Gold and Silver membership options, our 400 company members and their staff can benefit from a wide variety of savings, profiling opportunities, and more.
About One Nucleus
One Nucleus is a not-for-profit Life Sciences & Healthcare membership organisation headquartered in Cambridge. We support institutions, companies and individuals in the Life Sciences sector providing local, UK-wide and international connectivity.
Machine Learning Scientist
ROLE OVERVIEW
We are currently looking for a Machine Learning Scientist to join a leading pharmaceutical company based in the Cambridge area. As the Machine Learning Scientist, you will be responsible for driving the development of innovative machine learning methods for structure-based drug discovery.
KEY DUTIES AND RESPONSIBILITIES:
Your duties as the Machine Learning Scientist will be varied however the key duties and responsibilities are as follows:
Principal Scientist – Discovery & Translational Biology
A fantastic opportunity has arisen for a Principal Scientist – Discovery & Translational Biology to join a high-potential drug-development start-up, who are focussed on developing new oncology therapeutics that significantly improve overall survival for patients with a high unmet need. Our client is at the cutting edge of oncology therapeutics, triggering a new wave in target discovery by using proprietary algorithms to identify novel protein fingerprints from a comprehensive membrane protein database.
What’s Keeping Future Leaders Hidden?
There can often be a big distinction between how some people visibly and quickly rise in a workplace whilst others stay out of sight. The easy assumption to make is that they are not ready or capable. But when leadership potential goes unrecognised, it’s not always about lack of talent but can be a quiet accumulation of bias, assumptions, and outdated norms.
Eight Cardio Startups Kick Off Business Growth Programme at Discovery Park
Sandwich, UK - 10 September 2025: Discovery Park, Kent’s thriving life science and innovation community, today welcomed eight promising cardiovascular and cardiometabolic health startups to its campus. The cohort are embarking on the ‘Discovery Spark’ business growth programme, championing and supporting early stage business working on innovations in heart health.
Coulter Partners places COO at Cell and Gene Therapy Catapult
LONDON, September 10, 2025 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully completed a search assignment for the Cell and Gene Therapy Catapult (CGT Catapult) and is pleased to announce the placement of Dr. Ed Samuel as Chief Operations Officer (COO).
Medicilon Receives International Accreditation Again! Successfully Obtains OECD GLP Certification Certificate
Recently, Medicilon officially obtained the Good Laboratory Practice (GLP) certification certificate issued by Mexico, a member country of the OECD. In addition, we successfully passed GLP on-site inspections conducted by Hungary.
Following recent FDA and PMDA GLP audits, this achievement reaffirms that Medicilon’s preclinical research quality continues to meet the highest international standards.
Membrane Protein Preparation Protocol: Unlocking Hidden Biology
Creative Biolabs delivers customized preparation solutions to solve the tough challenges facing membrane protein discovery, ensuring to yield proteins that remain functional and ready for downstream applications.
Myricx Bio Appoints Jonathon Marks-Bluth as VP, Business Development
London, UK, 8 September 2025 – Myricx Bio (‘Myricx’), a UK-based biotech company focusing on the discovery and development of a completely novel class of payloads for antibody-drug conjugates (ADCs), is pleased to announce the appointment of Jonathon Marks-Bluth, Ph.D., to its leadership team in the newly created position of VP, Business Development.
NRG Therapeutics Announces Oversubscribed £50m ($67m) Series B Financing to Deliver Clinical Data in Parkinson’s and Proof of Concept in ALS/MND
• Oversubscribed £50m Series B led by SV Health Investors’ Dementia Discovery Fund, alongside other new investors British Business Bank, M Ventures, Novartis Venture Fund and Criteria Bio Ventures, together with existing investors Omega Funds and Brandon Capital
• The financing will enable NRG Therapeutics to deliver clinical proof of concept in ALS/MND with NRG5051, a first-in-class, oral inhibitor of the mitochondrial permeability transition pore (mPTP)